HomeGeneticsGeneCDKN2A gene
Back to Gene
CDKN2A gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

CDKN2A gene

The CDKN2A gene provides instructions for producing tumor suppressor proteins that regulate the cell cycle and prevent uncontrolled cell growth.

Normal Function

The CDKN2A gene provides instructions for making several proteins, the most well-studied being p16(INK4A) and p14(ARF). Both function as tumor suppressors, keeping cells from growing and dividing too rapidly or in an uncontrolled way. They are also involved in stopping cell division in older cells, a process known as senescence.

The p16(INK4A) protein binds to CDK4 and CDK6. These proteins normally stimulate the cell to continue through the cell cycle and divide. By binding to them, p16(INK4A) blocks their ability to stimulate cell cycle progression, effectively controlling cell division.

The p14(ARF) protein protects a protein called p53 from being broken down. p53 is an important tumor suppressor essential for regulating cell division, senescence, and self-destruction (apoptosis). By protecting p53, p14(ARF) helps prevent tumor formation.

Health Conditions Related to Genetic Changes

Head and neck squamous cell carcinoma

Mutations in the CDKN2A gene are found in up to one-quarter of head and neck squamous cell carcinomas. These somatic mutations are acquired during a person's lifetime and are found only in tumor cells. Most lead to little or no functional p16(INK4A) protein, allowing cells to grow and divide without control.

Additionally, a process called promoter hypermethylation can turn off the production of p16(INK4A) or p14(ARF), also leading to unchecked cell growth.

Melanoma

CDKN2A gene mutations are associated with up to 40 percent of familial cases of melanoma. These germline mutations are typically inherited and present in essentially all of the body's cells. These mutations result in a nonfunctional p16(INK4A) protein. In many cases, a second somatic mutation or deletion occurs in the normal copy of the gene in melanocytes, leading to the formation of a melanoma.

Individuals with a CDKN2A mutation tend to develop melanoma at an earlier age and have an increased risk of other cancers, particularly of the pancreas or lung.

Other Cancers

Germline mutations in CDKN2A are associated with breast and pancreatic cancers. In some families, these mutations lead to a cancer predisposition syndrome, increasing the risk of developing multiple types of cancer. Somatic mutations have also been identified in some brain tumors and in children with acute lymphoblastic leukemia.

Frequently Asked Questions

positive germline CDKN2A mutation markedly increases lifetime risk of melanoma (up to 70‑80%) and also raises risk for pancreatic cancer and, to a lesser extent, other solid tumors. You should begin dermatologic skin exams every 6‑12 months, consider annual whole‑body skin checks, and use strict sun protection. Discuss pancreatic cancer screening (MRI or endoscopic ultrasound) with a gastroenterologist, especially after age 50 or if there is a strong family history. Regular oral examinations are advised because head‑and‑neck cancers are also modestly elevated.
Somatic CDKN2A loss in a tumor indicates that the cancer cells lack functional p16, which can influence prognosis and may make the tumor more sensitive to CDK4/6 inhibitors or immunotherapy, depending on the cancer type. However, it does not imply a hereditary cancer syndrome, so your personal surveillance remains based on standard guidelines for that cancer. Discuss targeted therapy options with your oncologist, who may order molecular profiling to see if a CDK4/6 inhibitor is appropriate.
If a pathogenic CDKN2A variant is confirmed in the family, cascade testing of first‑degree relatives is recommended. Testing can be done at any age, but many clinicians suggest waiting until the child is old enough to understand the implications (often around 10‑12 years). Early‑identified carriers should start rigorous sun protection, regular dermatologic exams, and education about skin self‑exams. Some families also consider enrolling in research registries for early‑detection trials.
While genetics set a baseline risk, modifiable factors still matter. Strict UV protection (broad‑spectrum sunscreen SPF 30+, protective clothing, avoiding peak sun hours) is the most important. Avoid tanning beds, limit alcohol intake, maintain a healthy weight, and stay physically active, as obesity can increase melanoma risk. Discuss vitamin D monitoring with your doctor, as excessive sun avoidance may affect levels. Regular skin checks remain essential regardless of lifestyle.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss